Hypoxia-directed cancer therapy

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 6, 2002, Pages 777-788

  Mabjeesh, Nicola J ^a   Frazier, Monica C ^a   Simons, Jonathan W ^a   Zhong, Hua ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; HIF 1; Hypoxia directed therapy; Neoplasm

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANSAMYCIN DERIVATIVE; BENZOIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; ENZYME INHIBITOR; FK 506 BINDING PROTEIN; GELDANAMYCIN; GYRASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITROIMIDAZOLE; NITROIMIDAZOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PORPHYRIN DERIVATIVE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PYRUVATE KINASE; RADICICOL; RADIOSENSITIZING AGENT; TIRAPAZAMINE; UNINDEXED DRUG; VASCULOTROPIN; WORTMANNIN;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN TISSUE; HYPOXIA; MOUSE; NONHUMAN; OXYGEN SUPPLY; REVIEW; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; TRANSCRIPTION INITIATION; VIRAL GENE THERAPY;

EID: 0036075879     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.6.777     Document Type: Review

References (106)

1. Hypoxic fractions of solid tumours: Experimental techniques, methods of analysis and a survey of existing data
2. 2 tension measurements
3. Imaging of hypoxia in human tumours with [F-18] fluoromisonidazole
4. Hypoxic heterogeneity in human tumours: EF5 binding, vasculature, necrosis and proliferation
5. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies
6. Noninvasive determination of tumour oxygen tension and local variation with growth
7. 2 gradients in solid tumours in vivo: High-resolution measurements reveal a lack of correlation
8. Regional tumour oxygen dynamics: 19F PBSR EPI of hexafluorobenzene
9. Tumour hypoxia adversely affects the prognosis of carcinoma of the head and neck
10. Oxygenation predicts radiation response and survival in patients with cervix cancer
11. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
12. Oxygen status of malignant tumours: Pathogenesis of hypoxia and significance for tumour therapy
13. Tumour angiogenesis: Therapeutic implications
14. Angiogenesis and tumour metastasis
15. The biology of vascular endothelial growth factor
16. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
17. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
18. Upregulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumour angiogenesis
19. Hypoxia regulatory elements of the human vascular endothelial growth factor gene
20. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo
21. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer
22. Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia
23. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
24. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signalling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element
25. Oncogenic alterations of metabolism
26. 'The metabolism of tumours': 70 years later
27. Lactate metabolism in patients with cancer
28. Correlation of high lactate levels in human cervical cancer with incidence of metastasis
29. Correlation of high lactate levels in head and neck tumours with incidence of metastasis
30. 2 involved in biochemical strategy of energy generation in neoplastic cells
31. Glucose catabolism in cancer cells. The Type II hexokinase promoter contains functionally active response elements for the tumour suppressor p53
32. Aberrant glycolytic metabolism of cancer cells: A remarkable coordination of genetic, transcriptional, post-translational and mutational events that lead to a critical role for Type II hexokinase
33. FDG uptake, tumour characteristics and response to therapy: A review
34. Mammalian hexokinases and their abnormal expression in cancer
35. An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: Role in tumour cell glycolysis and the Warburg effect
36. Involvement of hypoxia-inducible factor 1 in human cancer
37. HIF-1 and tumour progression: Pathophysiology and therapeutics
38. Activation of the HIF pathway in cancer
39. Hypoxia-a key regulatory factor in tumour growth
40. Hypoxia-inducible factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth
41. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumour progression
42. HIF-1α is required for solid tumour formation and embryonic vascularization
43. Hypoxia-inducible factor-1α is a positive factor in solid tumour growth
44. Biological consequences of tumour hypoxia
45. Hyperbaric oxygen and radiotherapy: A Medical Research Council trial in carcinoma of the bladder
46. Results of an RTOG Phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas
47. New antimetastatic hypoxic cell radiosensitizers: Design, synthesis and biological activities of 2-nitroimidazole-acetamide, TX-1877 and its analogues
48. PR-000350, a novel hypoxic radiosensitizer, enhances tumour cell killing by promoting apoptosis preferentially in the S-phase fraction
49. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas
50. Tirapazamine: A new drug producing tumour specific enhancement of platinum-based chemotherapy in nonsmall-cell lung cancer
51. Bioreductive and gene therapy approaches to hypoxic diseases
52. Tirapazamine plus cisplatin versus cisplatin in advanced nonsmall-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Tumours
53. Phase I trial of concurrent tirapazamine, cisplatin and radiotherapy in patients with advanced head and neck cancer
54. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated antitumour agent
55. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N
56. A preclinical pharmacokinetic study of the bioreductive drug AQ4N
57. AQ4N: A new approach to hypoxia-activated cancer chemotherapy
58. Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs
59. Effect of cyclic polylactates on tumour cells and tumour bearing mice
60. 2 tension
61. HIF-1 and mechanisms of hypoxia sensing
62. Dimerization, DNA binding and transactivation properties of hypoxia- inducible factor 1
63. Redox-regulated recruitment of the transcriptional co-activators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1α
64. Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxia: Their stabilization and redox signal-induced interaction with CBP/p300
65. HIF-1, O(2) and the 3 PHDs: How animal cells signal hypoxia to the nucleus
66. 2-regulated prolyl hydroxylation
67. 2 sensing
68. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation
69. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch
70. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases
71. The expression and distribution of the hypoxia-inducible factors HIF- 1α and HIF-2α in normal human tissues, cancers and tumour- associated macrophages
72. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTENAKT/FRAP pathway in human prostate cancer cells: Implications for tumour angiogenesis and therapeutics
73. Suppression of tumour growth through disruption of hypoxia-inducible transcription
74. Hsp90: Chaperoning signal transduction
75. Functional interference between hypoxia and dioxin signal transduction pathways: Competition for recruitment of the Arnt transcription factor
76. Hypoxia-induced activation of HIF-1: Role of HIF-1α-Hsp90 interaction
77. Heat induction of the unphosphorylated form of hypoxia-inducible factor- 1α is dependent on heat-shock protein-90 activity
78. Geldanamycin induces degradation of HIF-1α protein via the proteosome pathway in prostate cancer cells
79. Dephosphorylated hypoxia-inducible factor 1α as a mediator of p53-dependent apoptosis during hypoxia
80. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible Factor-1α and Vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts
81. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy
82. Heterogeneity of angiogenic activity in a human liposarcoma: A proposed mechanism for 'no take' of human tumours in mice
83. Phosphatidylinositol 3-kinase signalling controls levels of hypoxia-inducible factor 1
84. HER2 (neu) signalling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
85. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1α in rasV12 upregulation of VEGF
86. Normoxic induction of the hypoxia-inducible factor 1α by insulin and interleukin-1β involves the phosphatidylinositol 3-kinase pathway
87. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells
88. HIF-1 expression in healing wounds: HIF-1α induction in primary inflammatory cells by TNF-α
89. A nonhypoxic, ROS-sensitive pathway mediates TNF-α-dependent regulation of HIF-1α
90. Interleukin-1β and tumour necrosis factor-α stimulate DNA binding of hypoxia-inducible factor-1
91. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia- inducible factor (HIF)-1α, HIF-2α and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol pathway
92. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis
93. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumour cells in vitro and in vivo: Angiogenic implications transduction therapy of solid tumours
94. von Hippel Lindau tumour suppressor and HIF-1α: New targets of NSAIDs inhibition of hypoxia-induced angiogenesis
95. A new HIF-1α variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses
96. Inhibitory PAS domain protein is a negative regulator of hypoxia- inducible gene expression
97. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells
98. Development of a hypoxia-responsive vector for tumour-specific gene therapy
99. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells
100. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy
101. Expression of HIF-1α by human macrophages: Implications for the use of macrophages in hypoxia-regulated cancer gene therapy
102. 'Accidental' antiangiogenic drugs. Antioncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
103. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
104. 2 homeostasis by hypoxia-inducible factor 1α
105. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT
106. Nuclear expression of hypoxia-inducible factor 1α protein is heterogeneous in human malignant cells under normoxic conditions